CU Anschutz Launches First-in-Class Phase 1 Trial Combining PARP Inhibitor with Novel WNT Pathway Modulator for Resistant Ovarian Cancer
核心洞察
Researchers at the University of Colorado Cancer Center have launched the first clinical trial combining PARP (搜索) inhibitors with SM08502 (Cirtuvivint), targeting resistant ovarian cancer (搜索) through dual mechanisms.
The combination therapy addresses PARP inhibitor (搜索) resistance by targeting WNT signaling (搜索), a backup survival system activated when cancer cells become resistant to PARP (搜索) drugs.
Laboratory studies demonstrated that SM08502 alone slowed tumor growth, while the combination enhanced cancer cell death, increased DNA damage, and reduced immune suppression.
Researchers at the University of Colorado Cancer Center have launched a groundbreaking Phase 1 clinical trial testing a novel combination therapy for ovarian cancer (搜索) patients who no longer respond to existing treatments. The study, published in Cancer Research Communications, represents the first clinical trial to combine PARP (搜索) inhibitors with SM08502 (Cirtuvivint), targeting cancer through dual mechanisms to overcome treatment resistance.
Addressing PARP Inhibitor Resistance Through WNT Pathway Modulation
The research addresses a critical challenge in ovarian cancer (搜索) treatment, particularly for high-grade serous ovarian cancer (搜索) patients. While PARP (搜索) inhibitors have transformed care for patients with BRCA genetic mutations or homologous recombination deficiency (HRD) over the past decade, significantly extending survival rates, many patients eventually develop resistance to these drugs, leaving limited treatment alternatives.
"This achievement exemplifies true bench-to-bedside innovation entirely done at CU Anschutz (搜索)," said Bradley Corr, MD, the paper's first author and associate professor and director of clinical research in gynecologic oncology at CU Anschutz. "To the best of our knowledge, this is the first clinical trial to successfully combine these classes of drugs. While the concept has been discussed before, no one has moved it into the clinic until now. That's what makes this approach truly novel."
The CU Cancer Center team discovered that when cancer cells become resistant to PARP (搜索) inhibitors, they activate a "backup survival system" called WNT signaling (搜索), enabling continued cancer growth despite PARP inhibition. This finding led researchers to investigate SM08502 (Cirtuvivint), which indirectly shuts down WNT signaling by modifying how certain cancer genes are processed, rather than directly blocking the pathway.
Promising Laboratory Results Drive Clinical Translation
Laboratory studies revealed impressive anti-cancer effects from the combination approach. SM08502 demonstrated tumor growth inhibition as a single agent, while the combination with PARP (搜索) inhibitors such as Olaparib produced enhanced therapeutic effects including increased cancer cell death, greater DNA damage that impairs cancer survival, and reduced immune suppression that allows the body's immune system to fight cancer more effectively.
"I began my career focused on understanding why ovarian cancer (搜索) becomes resistant to therapy. PARP (搜索) inhibitors have been a cornerstone of my research, but resistance remains a major challenge," said senior author Benjamin Bitler, PhD, associate professor and the D. Thomas and Kay L. Dunton Endowed Chair in Ovarian Cancer Research at CU Anschutz (搜索). "Early on, we characterized therapy-resistant cell lines, and this research represents the next step - developing strategies to help patients who may have no other options."
Dual-Target Strategy Offers New Treatment Paradigm
This combination therapy represents the first treatment approach to simultaneously target both PARP (搜索) and WNT signaling (搜索) pathways, limiting cancer cells' survival mechanisms and potentially improving treatment effectiveness. The dual-target strategy addresses the fundamental challenge of cancer's ability to develop alternative survival pathways when primary treatment mechanisms are blocked.
Both drugs are administered orally, making treatment more accessible for patients. The researchers note that this approach has potential applications beyond ovarian cancer (搜索), extending to other tumors with similar resistance mechanisms. Additionally, the combination may help reduce risks associated with long-term PARP inhibitor (搜索) use.
Bitler credits CU Anschutz (搜索)'s collaborative ecosystem and the partnership with clinicians like Corr for enabling this milestone transition from laboratory discovery to clinical application, representing a complete bench-to-bedside innovation conducted entirely at the institution.